Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566890 · ClinicalTrials.gov registry record · NA
Microvascular Blood Flow in Sickle Cell Anemia
A NA study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Versiti Blood Health.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT01566890 is a NA study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Versiti Blood Health. The registered enrollment target is 91 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01566890, a NA study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Versiti Blood Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. Sickle-shaped cells can cause problems by getting stuck in blood vessels, blocking blood flow, and can cause inflammation and injury to important body parts. There are no specific treatments that improve this condition and promote blood flow hindered by sickle cell blockages. Another big challenge in managing sickle cell disease is that there are no good measures to determine changes and improvements in blood flow. Contrast-enhanced ultrasound is a technique currently used to detect blood flow in the heart, muscles, and other organs. It is extremely sensitive and can detect blood flow in the smallest of blood vessels. It would be very useful in helping healthcare providers know whether treatment strategies are improving blood flow during sickle cell blockages. The hypothesis is that contrast-enhanced ultrasound will be a feasible tool for determining changes in blood flow of subjects with sickle cell disease.
Conditions Studied
Interventions
- DRUG regadenoson infusion with contrast-enhanced ultrasound
- PROCEDURE contrast-enhanced ultrasound
Study Locations (2)
Illinois
- The University of Illinois - Chicago
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2012-07 |
| Est. Completion | 2020-11-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01566890
The ClinicalTrials.gov registry entry for NCT01566890 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The listed sponsor is Versiti Blood Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which regadenoson infusion with contrast-enhanced ultrasound is the first listed.
NCT01566890 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01566890 about?
NCT01566890 is a clinical study titled "Microvascular Blood Flow in Sickle Cell Anemia". Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. Sickle-shaped cells can cause problems by getting stuck in blood vessels, blocking blood flow, and can cause inflammation and in...
What is the current status of trial NCT01566890?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2012-07. Estimated completion is 2020-11-16.
What conditions does trial NCT01566890 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia.
What interventions are being tested in trial NCT01566890?
The interventions under investigation include: regadenoson infusion with contrast-enhanced ultrasound (DRUG), contrast-enhanced ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT01566890?
This trial is sponsored by Versiti Blood Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01566890 being conducted?
This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.